glp 1 agonist herbal Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Do GLP-1 Patches Really Work?

CB-839 is a highly potent allosteric inhibitor that completed phase I clinical trials in March 2019 in patients with advanced RCC (NCT02071862) and has in 2020 moved to phase II clinical trials in patients with non-small cell lung cancer (NCT04265534)

In vitro, Apt-1 disrupted the maintenance (but not initiation) of the myCAF phenotype and reduced cancer stemness markers (Sox2, Oct4, Nanog), leading to a significant decrease in tumorsphere formation

Hepcidin is negatively regulated by TMPRSS6, which inhibits hepcidin expression by suppressing Hjv activity and the bone morphogenetic protein-signaling pathway

This can deter patients from sticking with the B12 treatment plan, but it is important to stay consistent

Additionally, some evidence suggests that MSM can boost the immune system and may have cancer-fighting properties

May 1995;57(5):552-8